Stamler: “In the ATH434-202 trial, the participants who stabilized or improved with ATH434 treatment had less advanced disease than those who progressed". The speed of increasing MSA-rating is at its highest in these early cases according to the "Wenning et al"-paper if my understanding is correct.
It is best to wait for new 6-month and 12-month cases during the autumn to get a clearer picture.
- Forums
- ASX - By Stock
- ATH
- Good to look at the reference study by Wenning et al
Good to look at the reference study by Wenning et al, page-2
Featured News
Add ATH (ASX) to my watchlist
|
|||||
Last
0.6¢ |
Change
-0.001(14.3%) |
Mkt cap ! $31.47M |
Open | High | Low | Value | Volume |
0.5¢ | 0.6¢ | 0.5¢ | $648.3K | 128.1M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 4901441 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 22097257 | 20 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 4901441 | 0.005 |
101 | 94381728 | 0.004 |
56 | 46194100 | 0.003 |
16 | 32514403 | 0.002 |
15 | 95820101 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 22097257 | 20 |
0.007 | 20976858 | 19 |
0.008 | 31046938 | 32 |
0.009 | 14798789 | 13 |
0.010 | 12395581 | 12 |
Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
Featured News
ATH (ASX) Chart |